Studies identify more effective treatment for malaria control during pregnancy in AfricaJune 20, 2007A review of previous studies indicates that two doses of a malaria preventive therapy during pregnancy provides substantial benefit to HIV-negative women in Africa, with more frequent dosing apparently necessary for HIV-positive women, according to an article in the June 20 issue of JAMA. In malaria-endemic regions, the burden of disease is primarily in young children and pregnant women. Women are particularly vulnerable to the adverse effects of malaria during their first and second pregnancies, according to background information in the article. Approximately 50 million women living in malaria-endemic areas become pregnant each year, half in areas of sub-Saharan Africa with stable Plasmodium falciparum (a parasite that causes malaria) transmission. In these regions, strategies to control malaria during pregnancy rely on case management of malaria illness and anemia, and a variety of preventive measures that consists of insecticide-treated nets (ITNs) and intermittent preventive therapy (IPT) with the malaria drug sulfadoxine-pyrimethamine. Feiko ter Kuile, M.D., Ph.D., of the Liverpool School of Tropical Medicine, Liverpool, England and colleagues evaluated data to assess whether increasing the frequency of IPT with sulfadoxine-pyrimethamine during pregnancy could provide a temporary respite in areas in Africa with increasing sulfadoxine-pyrimethamine resistance. The researchers identified four trials that compared 2-dose IPT with sulfadoxine-pyrimethamine to case management or placebo in women during their first or second pregnancy. The IPT reduced the risk of placental malaria by 52 percent, the risk of low birth weight by 29 percent, and the risk of anemia by 10 percent. The effect did not vary by sulfadoxine-pyrimethamine resistance levels (range, 19 percent-26 percent). Efficacy of IPT with sulfadoxine-pyrimethamine was lower among women using insecticide-treated nets. Three trials compared 2-dose with monthly IPT with sulfadoxine-pyrimethamine during pregnancy. Among HIV-positive women in their first or second pregnancy, monthly IPT resulted in less placental malaria and higher birth weight over the range of sulfadoxine-pyrimethamine resistance tested (8 percent-39 percent). Among HIV-negative women, there was no conclusive additional effect of monthly dosing. "The deleterious effects of malaria during pregnancy can be substantially reduced by using IPT in pregnant women. Sulfadoxine-pyrimethamine is currently the only single-dose long-acting antimalarial drug that has ideal properties (low cost, documented safety, and ease of use) for use as an IPT during pregnancy. The current appraisal of available data on the efficacy of IPT with sulfadoxine-pyrimethamine as a function of sulfadoxine-pyrimethamine treatment responses in children provides policy makers with a clearer understanding of the value of different IPT regimens with sulfadoxine-pyrimethamine during pregnancy in the context of increasing sulfadoxine-pyrimethamine drug resistance," the authors write. "Reserving the use of sulfadoxine-pyrimethamine for IPT during pregnancy and for infants may reduce drug pressure and may prolong longevity of this valuable drug. Almost all countries in Africa are taking this course and have either implemented or are in the process of implementing the use of combination therapy for first-line treatment in the population, mostly with artemisinin-based [a type of antimalarial drug] combinations. This will also limit the options to monitor the degree of sulfadoxine-pyrimethamine resistance in treatment studies in children in vivo, and future studies that aim to determine the effect of sulfadoxine-pyrimethamine resistance on the efficacy of IPT with sulfadoxine-pyrimethamine during pregnancy may need to rely on molecular markers." JAMA and Archives Journals |
|||||||||||||||||||||
| Related Malaria Current Events and Malaria News Articles On the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites. Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease. Small nanoparticles bring big improvement to medical imaging If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging. Prioritizing low-cost, simple health measures would save 2.5 million child lives a year Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. DNA barcodes: Creative new uses span health, fraud, smuggling, history, more The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. Global challenges and opportunities in fighting HIV/AIDS and neglected diseases Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. More Malaria Current Events and Malaria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||